相关临床试验
8
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
已完成
8
100.0%
暂无批准数据
- AstraZeneca Pharma India reported a turnover of ₹2,275.58 crore for FY 2025-26, with export sales contributing ₹117.56 crore (5.2% of total turnover). - The company has ceased all manufacturing operations, marking a fundamental strategic shift to an office-based business model serving Pan-India and international markets including Nepal. - The company's net worth stood at ₹872.79 crore, with board diversity reaching 83.33% women directors (5 out of 6 board members). - KPMG Assurance and Consulting Services LLP provided limited assurance on the BRSR Core Indicators, reinforcing the credibility of the company's sustainability disclosures.
- AstraZeneca Pharma India Limited has received permission from India's Central Drugs Standard Control Organization to import and distribute Datopotamab Deruxtecan powder for infusion. - The approval covers treatment of adult patients with unresectable or metastatic, hormone receptor-positive, HER2-negative breast cancer who have received prior endocrine therapy and chemotherapy. - This regulatory milestone enables marketing of the 100 mg powder for concentrate formulation under the brand name Datverzo in India for the specified indication.
